Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Deferred Revenue: 2022-2024

Historic Current Deferred Revenue for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $19.0 million.

  • Stoke Therapeutics' Current Deferred Revenue fell 81.77% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 81.77%. This contributed to the annual value of $19.0 million for FY2024, which is 24.05% up from last year.
  • As of FY2024, Stoke Therapeutics' Current Deferred Revenue stood at $19.0 million, which was up 24.05% from $15.3 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Current Deferred Revenue ranged from a high of $19.0 million in FY2024 and a low of $14.9 million during FY2022.
  • Over the past 3 years, Stoke Therapeutics' median Current Deferred Revenue value was $15.3 million (recorded in 2023), while the average stood at $16.4 million.
  • Data for Stoke Therapeutics' Current Deferred Revenue shows a peak YoY grew of 24.05% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Stoke Therapeutics' Current Deferred Revenue stood at $14.9 million in 2022, then rose by 2.88% to $15.3 million in 2023, then climbed by 24.05% to $19.0 million in 2024.